BioPartnering Europe (BPE) continues to attract top international decision makers
Advertisement
Technology Vision Group LLC is pleased to announce that as the BioPartnering Europe (BPE) conference enters its 13th year, its popularity is continuing to grow. BPE (October 9-11) has been chosen to kick off the World life science Week, which will continue with CORDIA (October 11-13). Delegate numbers for BPE have risen by over 10% last month, with well over 350 delegates from Europe, the US and Asia now registered to attend. The Open House and Emerging Company presentation slots are also filling up with 127 companies now registered to present. Latest data on the registrants show that BPE is once again attracting key international decision makers from pharmaceutical, biotechnology and financial companies and is maintaining its reputation as one of the most valuable biotech events in the world for partnering and business development opportunities.
One of the trademarks of BPE, and a reason for its continued success, is the conference's distinctive BioPartnering Leadership Sessions in which some of the most important issues effecting the growth of the life-science industry today are debated by a group of key industrial leaders. One of these sessions, entitled, "BioPartnering and Liquidity Events: Strategies for Success" will call into question the reliance upon corporate partnering deals to achieve success in today's business climate, with its challenging capital markets and increasing focus on late-stage products and top-line revenue. The chair of this session, Mr. Barclay J. Kamb, Partner, Cooley Godward LLP, whose firm is also a sponsor of BPE, commented:
"In the BioPartnering Leadership Sessions, groups of industry experts provide to the conference delegates top-level discussions on current issues affecting the life-science industry. In a sector which is constantly evolving, it is vital that companies stay apprised of the latest trends which affect their business and partnering strategies. BPE is one of the most efficient and effective ways I know of keeping up to date with new developments; further, with its focus on biopartnering meetings, the conference also provides a fantastic opportunity to keep up with one's colleagues, foster new alliances and make deals."
This year BPE will once again feature Emerging Company presentations. Thirty companies from across Europe, the USA and the rest of the world are being selected to present in this session based on recommendations by investors; in fact several of the companies who have been featured in the past have gone on to become some of the industry's most important players. One of the companies due to present this year is London based biotechnology company Curidium. Dr. Anne Bruinvels, CEO commented,
"I have attended BPE many times in the past and have always come away with valuable business contacts so I am delighted to present Curidium in one of the Emerging Company presentations this year. For a growing company BPE provides an excellent platform to present our corporate objectives to an audience of leading pharma and biotech executives. It's a great business development opportunity."
Along with the BioPartnering Leadership Sessions and Emerging Company presentations, BPE will once again feature all the other trademarks that make it the biopartnering conference to attend - Open House presentations, Sponsor Workshops and networking opportunities.
Other news from the department business & finance
